Share-based Payment Arrangement, Expense of Coherus Oncology, Inc. from 31 Mar 2014 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: Coherus Oncology, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2014 to 30 Sep 2025.
Coherus Oncology, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,389,000, a 51% decline year-over-year.
Coherus Oncology, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $20,566,000, a 36% decline year-over-year.
Coherus Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $27,802,000, a 36% decline from 2023.
Coherus Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $43,110,000, a 15% decline from 2022.
Coherus Oncology, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $50,737,000, a 1.2% decline from 2021.
Source SEC data: View on sec.gov

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)

Share-based Payment Arrangement, Expense, Annual (USD)

Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Coherus Oncology, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025	$20,566,000	$3,389,000	-$3,479,000	-51%	01 Jul 2025	30 Sep 2025	10-Q	06 Nov 2025	2025	Q3
Q2 2025	$24,045,000	$5,421,000	-$1,810,000	-25%	01 Apr 2025	30 Jun 2025	10-Q	07 Aug 2025	2025	Q2
Q1 2025	$25,855,000	$5,372,000	-$1,947,000	-27%	01 Jan 2025	31 Mar 2025	10-Q	12 May 2025	2025	Q1
Q4 2024	$27,802,000	$6,384,000	-$4,414,000	-41%	01 Oct 2024	31 Dec 2024	8-K	13 Nov 2025
Q3 2024	$32,216,000	$6,868,000	-$3,085,000	-31%	01 Jul 2024	30 Sep 2024	10-Q	06 Nov 2025	2025	Q3
Q2 2024	$35,301,000	$7,231,000	-$2,846,000	-28%	01 Apr 2024	30 Jun 2024	10-Q	07 Aug 2025	2025	Q2
Q1 2024	$38,147,000	$7,319,000	-$4,963,000	-40%	01 Jan 2024	31 Mar 2024	10-Q	12 May 2025	2025	Q1
Q4 2023	$43,110,000	$10,798,000			01 Oct 2023	31 Dec 2023	8-K	13 Nov 2025
Q3 2023		$9,953,000			01 Jul 2023	30 Sep 2023	10-Q	06 Nov 2024	2024	Q3
Q2 2023		$10,077,000			01 Apr 2023	30 Jun 2023	10-Q	08 Aug 2024	2024	Q2
Q1 2023		$12,282,000			01 Jan 2023	31 Mar 2023	10-Q	09 May 2024	2024	Q1
Q1 2021		$800,000			01 Feb 2021	28 Feb 2021	10-K	15 Mar 2024	2023	FY
Q2 2015		$4,618,000	+$3,542,000	+329%	01 Apr 2015	30 Jun 2015	10-Q	10 Aug 2015	2015	Q2
Q1 2015		$2,176,000	+$1,685,000	+343%	01 Jan 2015	31 Mar 2015	10-Q	11 May 2015	2015	Q1
Q2 2014		$1,076,000			01 Apr 2014	30 Jun 2014	10-Q	10 Aug 2015	2015	Q2
Q1 2014		$491,000			01 Jan 2014	31 Mar 2014	10-Q	11 May 2015	2015	Q1

Period	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
2024	$27,802,000	-$15,308,000	-36%	01 Jan 2024	31 Dec 2024	8-K	13 Nov 2025
2023	$43,110,000	-$7,627,000	-15%	01 Jan 2023	31 Dec 2023	8-K	13 Nov 2025
2022	$50,737,000	-$627,000	-1.2%	01 Jan 2022	31 Dec 2022	10-K	17 Mar 2025	2024	FY
2021	$51,364,000	+$13,204,000	+35%	01 Jan 2021	31 Dec 2021	10-K	15 Mar 2024	2023	FY
2020	$38,160,000	+$4,569,000	+14%	01 Jan 2020	31 Dec 2020	10-K	06 Mar 2023	2022	FY
2019	$33,591,000	-$1,206,000	-3.5%	01 Jan 2019	31 Dec 2019	10-K	23 Feb 2022	2021	FY
2018	$34,797,000	+$1,400,000	+4.2%	01 Jan 2018	31 Dec 2018	10-K	25 Feb 2021	2020	FY
2017	$33,397,000	+$5,976,000	+22%	01 Jan 2017	31 Dec 2017	10-K	27 Feb 2020	2019	FY
2016	$27,421,000	+$10,700,000	+64%	01 Jan 2016	31 Dec 2016	10-K	28 Feb 2019	2018	FY
2015	$16,721,000			01 Jan 2015	31 Dec 2015	10-K	08 Mar 2018	2017	FY

* An asterisk sign (*) next to the value indicates that the value is likely invalid.